Zorrilla CD, Reyes Baez F, Gonzalez Colon K, Ibarra J, Garcia I, et al. HIV seroconversion during pregnancy and the need for pre-exposure prophylaxis (PrEP). HIV/AIDS – Research and Palliative Care . 2018 April; 10(22):57-61.

S.K. Shah, J. Kimmelman, A. D. Lyerly, H. F. Lynch, F. G. Miller, R. Palacios, C. A. Pardo, C. Zorrilla; Bystander risk, social value, and ethics of human research; Science13 Apr 2018: 158-159.

Zorrilla CD, García García I, García Fragoso L, De La Vega A. Zika Virus Infection in Pregnancy: Maternal, Fetal, and Neonatal Considerations. J Infect Dis. 2017 Dec 16; 216(suppl_10):S891-S896. doi: 10.1093/infdis/jix448. PubMed PMID: 29267916.

Zorrilla CD. The View from Puerto Rico – Hurricane Maria and Its Aftermath. N Engl J Med. 2017 Oct 11. doi: 10.1056/NEJMp1713196. [Epub ahead of print] PubMed PMID: 29019710.

Zorrilla CD, Mosquera AM, Rabionet SE, Rivera-Vinas JI, Sierra Vega DJ, et al. Cost Savings Related to Decreased Preterm Birth in a Program of Centering Pregnancy for Hispanic Women. MOJ Women’s Health. 2017 April 19; 5(1):1-5.

Zorrilla CD, Sanchez I, Mosquera AM, Sierra D, Lopez-Perez L, et al. Improved Infant Outcomes with Group Prenatal Care in Puerto Rico. Source Journal of Obstetrics and Gynaecology . 2017 February 06; 1(1).

Zorrilla CD, Mosquera AM, Rabionet SE, Rivera-Vinas J. HIV and ZIKA in Pregnancy: Parallel Stories and New Challenges. Obstetrics & Gynecology International Journal. 2016 December 15; 5(6)

Deschamps, M.M., Zorrilla, C.D., Morgan, C.A, Donastorg, Y., Metch, B., Madenwald, T., et al. (2013). Recruitment of Caribbean female commercial sex workers at high risk of HIV infection. Revista Panamericana de Salud Pública, 34(2), 92-98.

CD Zorrilla, R Wright, O. Osiyemi, S Yasin, B Baugh, K Brown, B Coate, P Verboven, J Mrus, R Falcon and TN Kakuda; Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily; HIV Medicine (2013) DOI: 10.1111/hiv.12047; PMID: 23731450.

Eley, T., Huang, S.P., Conradie, F., Zorrilla, C.D., Josipovic, D., Botes, M., et al. (2013). Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. Aids Research and Human Retroviruses, 29(10), 1287-1292.

Nelson, M., Amaya, G., Clumeck, N., Arns da cunha, C., Jayaweera, D., Junod, P., Li, T., Tebas, P., Stevens, M., Buelens, A., Vanveggel, S., Boven, K., Abusamra, L., Cahn, P, Zorrilla C. et al; Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials; Journal of Antimicrobial Chemotherapy; volume 67, issue 8, year 2012, pp. 2020 – 2028

Jiménez, J., Morales, M., Castro, E., Puig, M., Vélez, C.N., Santiago, L., et al. (2012). Levels of felt stigma among a group of people with HIV in Puerto Rico. Puerto Rico Health Sciences Journal, 31(2), 64-70.

Zorrilla, C.D., Rabionet S.E., Mosquera, A.M., & Ramírez, A.B. (2012). Biomedical HIV Prevention Strategies: state of the art and implications for public health policy in the Caribbean. Puerto Rico Health Sciences Journal, 31(3), 170-179.

López-Cepero, R., Lynch, L., Zorrilla, C., Leavitt, K., & de la Vega, A. (2011). Antenatal screening for Down syndrome with special considerations in the Puerto Rican population. Puerto Rico Health Sciences Journal, 30(4), 206-210.

F Conradie, C Zorrilla,D Josipovic,M Botes,O Osiyemi,E Vandeloise, T Eley, M Child, R Bertz,W Hu, V Wirtzand D McGrath; Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women; 2011 British HIV Association HIV Medicine (2011); DOI: 10.1111/j.1468-1293.2011.00927 PMID: 21569187.

Cohen, C.J., Andrade-Villanueva, J., Clotet, B., Fourie, J., Johnson, M.A., Ruxrungtham, K., et al. (2011). Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet, 378(9787), 229-237.